Logical model of the Belgian standard cancer registration form (Kankerregistratieformulier voor een nieuwe diagnose). This is what hospitals submit to the Belgian Cancer Registry through WBCR or via batch extraction for every new cancer diagnosis.

Distinct from BCRCancerCase, which models the published research dataset derived from these submissions plus registry follow-up.

Source (canonical): Bijlage 55 to the RIZIV Verordening of 28 July 2003, as amended by the Verordening of 15 December 2025 (Belgisch Staatsblad 23-12-2025, p. 96356).

Free-text patient name as entered on the form.

Patient date of birth.

Belgian national number (INSZ/NISS) or, when unavailable, the insurance fund number.

Sex of the patient.

Date of incidence (DD-MM-YYYY) per ENCR/IACR international guidelines.

Most reliable method by which the diagnosis was established. Codes: 2 = histology of primary tumour, 3 = histology of metastasis, 4 = cytology / haematology, 5 = technical investigation (RX, endoscopy, …), 6 = clinical, 7 = tumour marker (PSA, hCG, AFP, Ig, …), 8 = cytogenetic / molecular tests, 9 = unknown.

Score at incidence date. Codes: 0 = asymptomatic, normal activity; 1 = symptomatic but ambulatory; 2 = symptomatic, bedridden <50% per day; 3 = symptomatic, bedridden >50% per day; 4 = fully dependent, 100% bedridden.

ICD-O-3 topography of the primary tumour.

Laterality of the primary tumour. Codes: 1 = left, 2 = right, 3 = unpaired organ, NK = unknown.

ICD-O-3 morphology code (the part before the slash on the form).

ICD-O-3 behaviour code (the part after the slash on the form: benign / borderline / in situ / malignant primary / malignant metastatic / unknown).

Grade of differentiation. Codes: 1 = well, 2 = moderate, 3 = poor, 4 = undifferentiated / anaplastic, 5 = T-cell, 6 = B-cell, 7 = null-cell (not T / not B), 8 = NK cell, 9 = unknown.

Clinical T category (UICC TNM).

Clinical N category (UICC TNM).

Clinical M category (UICC TNM).

Pathological T category (UICC TNM).

Pathological N category (UICC TNM).

Pathological M category (UICC TNM).

Pathological T after neoadjuvant therapy.

Pathological N after neoadjuvant therapy.

Pathological M after neoadjuvant therapy.

Alternative staging classification used when applicable. Codes: 1 = Childhood Cancer Stage, 2 = FIGO, 3 = Lugano, 4 = Breslow (in mm), 5 = other.

Stage value within the chosen alternative classification (e.g. Breslow depth in mm, FIGO stage).

Whether the cancer treatment is part of a clinical study (Ja / Nee / Onbekend).

EudraCT identifier of the trial when clinical trial participation is Ja.

One row of the chronology table, filled in chronologically from incidence date and first treatment.

Unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces.

May be used to represent additional information that is not part of the basic definition of the element. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension.

There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.

May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions.

Modifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself).

There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.

Modifier extensions allow for extensions that cannot be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored. This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the definition of modifier extensions.

Chronology code. Codes: 5 = diagnosis; 10 = surgery; 11 = excision biopsy; 16 = HSCT autologous; 17 = HSCT allogeneic; 20 = external radiotherapy / brachytherapy; 21 = IORT; 22 = hadron therapy; 25 = concurrent chemoradiotherapy; 26 = concurrent radio-immunotherapy; 30 = radio-isotopes; 35 = phototherapy; 36 = topical therapy; 40 = chemotherapy / systemic therapy; 45 = targeted therapy (not 26, 60); 50 = hormonal therapy; 60 = immunotherapy (not 26, 66); 66 = concurrent chemo-immunotherapy; 70 = symptomatic / palliative; 75 = active surveillance / watchful waiting; 80 = other treatment (free-text comment required); 90 = no therapy; 95 = treatment refusal; 99 = unknown.

Hospital site identifier where the episode took place.

Episode start date.

Episode end date when known.

Free-text comment, required only for code 80 (other treatment).

MOC report(s) attached to the form. Only required for breast tumours per footnote 7 of Bijlage 55.

Logical model of the Belgian standard cancer registration form (Kankerregistratieformulier voor een nieuwe diagnose). This is what hospitals submit to the Belgian Cancer Registry through WBCR or via batch extraction for every new cancer diagnosis.

Distinct from BCRCancerCase, which models the published research dataset derived from these submissions plus registry follow-up.

Source (canonical): Bijlage 55 to the RIZIV Verordening of 28 July 2003, as amended by the Verordening of 15 December 2025 (Belgisch Staatsblad 23-12-2025, p. 96356).

Free-text patient name as entered on the form.

Patient date of birth.

Belgian national number (INSZ/NISS) or, when unavailable, the insurance fund number.

Sex of the patient.

Date of incidence (DD-MM-YYYY) per ENCR/IACR international guidelines.

Most reliable method by which the diagnosis was established. Codes: 2 = histology of primary tumour, 3 = histology of metastasis, 4 = cytology / haematology, 5 = technical investigation (RX, endoscopy, …), 6 = clinical, 7 = tumour marker (PSA, hCG, AFP, Ig, …), 8 = cytogenetic / molecular tests, 9 = unknown.

Score at incidence date. Codes: 0 = asymptomatic, normal activity; 1 = symptomatic but ambulatory; 2 = symptomatic, bedridden <50% per day; 3 = symptomatic, bedridden >50% per day; 4 = fully dependent, 100% bedridden.

ICD-O-3 topography of the primary tumour.

Laterality of the primary tumour. Codes: 1 = left, 2 = right, 3 = unpaired organ, NK = unknown.

ICD-O-3 morphology code (the part before the slash on the form).

ICD-O-3 behaviour code (the part after the slash on the form: benign / borderline / in situ / malignant primary / malignant metastatic / unknown).

Grade of differentiation. Codes: 1 = well, 2 = moderate, 3 = poor, 4 = undifferentiated / anaplastic, 5 = T-cell, 6 = B-cell, 7 = null-cell (not T / not B), 8 = NK cell, 9 = unknown.

Clinical T category (UICC TNM).

Clinical N category (UICC TNM).

Clinical M category (UICC TNM).

Pathological T category (UICC TNM).

Pathological N category (UICC TNM).

Pathological M category (UICC TNM).

Pathological T after neoadjuvant therapy.

Pathological N after neoadjuvant therapy.

Pathological M after neoadjuvant therapy.

Alternative staging classification used when applicable. Codes: 1 = Childhood Cancer Stage, 2 = FIGO, 3 = Lugano, 4 = Breslow (in mm), 5 = other.

Stage value within the chosen alternative classification (e.g. Breslow depth in mm, FIGO stage).

Whether the cancer treatment is part of a clinical study (Ja / Nee / Onbekend).

EudraCT identifier of the trial when clinical trial participation is Ja.

One row of the chronology table, filled in chronologically from incidence date and first treatment.

Chronology code. Codes: 5 = diagnosis; 10 = surgery; 11 = excision biopsy; 16 = HSCT autologous; 17 = HSCT allogeneic; 20 = external radiotherapy / brachytherapy; 21 = IORT; 22 = hadron therapy; 25 = concurrent chemoradiotherapy; 26 = concurrent radio-immunotherapy; 30 = radio-isotopes; 35 = phototherapy; 36 = topical therapy; 40 = chemotherapy / systemic therapy; 45 = targeted therapy (not 26, 60); 50 = hormonal therapy; 60 = immunotherapy (not 26, 66); 66 = concurrent chemo-immunotherapy; 70 = symptomatic / palliative; 75 = active surveillance / watchful waiting; 80 = other treatment (free-text comment required); 90 = no therapy; 95 = treatment refusal; 99 = unknown.

Hospital site identifier where the episode took place.

Episode start date.

Episode end date when known.

Free-text comment, required only for code 80 (other treatment).

MOC report(s) attached to the form. Only required for breast tumours per footnote 7 of Bijlage 55.

Logical model of the Belgian standard cancer registration form (Kankerregistratieformulier voor een nieuwe diagnose). This is what hospitals submit to the Belgian Cancer Registry through WBCR or via batch extraction for every new cancer diagnosis.

Distinct from BCRCancerCase, which models the published research dataset derived from these submissions plus registry follow-up.

Source (canonical): Bijlage 55 to the RIZIV Verordening of 28 July 2003, as amended by the Verordening of 15 December 2025 (Belgisch Staatsblad 23-12-2025, p. 96356).

Free-text patient name as entered on the form.

Patient date of birth.

Belgian national number (INSZ/NISS) or, when unavailable, the insurance fund number.

Sex of the patient.

Date of incidence (DD-MM-YYYY) per ENCR/IACR international guidelines.

Most reliable method by which the diagnosis was established. Codes: 2 = histology of primary tumour, 3 = histology of metastasis, 4 = cytology / haematology, 5 = technical investigation (RX, endoscopy, …), 6 = clinical, 7 = tumour marker (PSA, hCG, AFP, Ig, …), 8 = cytogenetic / molecular tests, 9 = unknown.

Score at incidence date. Codes: 0 = asymptomatic, normal activity; 1 = symptomatic but ambulatory; 2 = symptomatic, bedridden <50% per day; 3 = symptomatic, bedridden >50% per day; 4 = fully dependent, 100% bedridden.

ICD-O-3 topography of the primary tumour.

Laterality of the primary tumour. Codes: 1 = left, 2 = right, 3 = unpaired organ, NK = unknown.

ICD-O-3 morphology code (the part before the slash on the form).

ICD-O-3 behaviour code (the part after the slash on the form: benign / borderline / in situ / malignant primary / malignant metastatic / unknown).

Grade of differentiation. Codes: 1 = well, 2 = moderate, 3 = poor, 4 = undifferentiated / anaplastic, 5 = T-cell, 6 = B-cell, 7 = null-cell (not T / not B), 8 = NK cell, 9 = unknown.

Clinical T category (UICC TNM).

Clinical N category (UICC TNM).

Clinical M category (UICC TNM).

Pathological T category (UICC TNM).

Pathological N category (UICC TNM).

Pathological M category (UICC TNM).

Pathological T after neoadjuvant therapy.

Pathological N after neoadjuvant therapy.

Pathological M after neoadjuvant therapy.

Alternative staging classification used when applicable. Codes: 1 = Childhood Cancer Stage, 2 = FIGO, 3 = Lugano, 4 = Breslow (in mm), 5 = other.

Stage value within the chosen alternative classification (e.g. Breslow depth in mm, FIGO stage).

Whether the cancer treatment is part of a clinical study (Ja / Nee / Onbekend).

EudraCT identifier of the trial when clinical trial participation is Ja.

One row of the chronology table, filled in chronologically from incidence date and first treatment.

Unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces.

May be used to represent additional information that is not part of the basic definition of the element. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension.

There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.

May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions.

Modifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself).

There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.

Modifier extensions allow for extensions that cannot be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored. This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the definition of modifier extensions.

Chronology code. Codes: 5 = diagnosis; 10 = surgery; 11 = excision biopsy; 16 = HSCT autologous; 17 = HSCT allogeneic; 20 = external radiotherapy / brachytherapy; 21 = IORT; 22 = hadron therapy; 25 = concurrent chemoradiotherapy; 26 = concurrent radio-immunotherapy; 30 = radio-isotopes; 35 = phototherapy; 36 = topical therapy; 40 = chemotherapy / systemic therapy; 45 = targeted therapy (not 26, 60); 50 = hormonal therapy; 60 = immunotherapy (not 26, 66); 66 = concurrent chemo-immunotherapy; 70 = symptomatic / palliative; 75 = active surveillance / watchful waiting; 80 = other treatment (free-text comment required); 90 = no therapy; 95 = treatment refusal; 99 = unknown.

Hospital site identifier where the episode took place.

Episode start date.

Episode end date when known.

Free-text comment, required only for code 80 (other treatment).

MOC report(s) attached to the form. Only required for breast tumours per footnote 7 of Bijlage 55.